ID20117A - Antibodi anti-fas - Google Patents

Antibodi anti-fas

Info

Publication number
ID20117A
ID20117A IDP980478A ID980478A ID20117A ID 20117 A ID20117 A ID 20117A ID P980478 A IDP980478 A ID P980478A ID 980478 A ID980478 A ID 980478A ID 20117 A ID20117 A ID 20117A
Authority
ID
Indonesia
Prior art keywords
fas
fas antibody
human
abnormalities
mouse
Prior art date
Application number
IDP980478A
Other languages
English (en)
Inventor
Nobufusa Serizawa
Kimihisa Ichikawa
Jun Ohsumi
Masahiko Ohtsuki
Hideyuki Haruyama
Tohru Takahashi
Hiroko Yoshida
Akio Shiraishi
Shin Yinehara
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of ID20117A publication Critical patent/ID20117A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IDP980478A 1997-04-01 1998-03-31 Antibodi anti-fas ID20117A (id)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP8295397 1997-04-01
JP16908897 1997-06-25
JP27606497 1997-10-08

Publications (1)

Publication Number Publication Date
ID20117A true ID20117A (id) 1998-10-01

Family

ID=27304060

Family Applications (1)

Application Number Title Priority Date Filing Date
IDP980478A ID20117A (id) 1997-04-01 1998-03-31 Antibodi anti-fas

Country Status (17)

Country Link
EP (1) EP0909816A1 (id)
KR (1) KR19980080993A (id)
CN (1) CN1207395A (id)
AR (1) AR010139A1 (id)
AU (1) AU734758B2 (id)
BR (1) BR9803296A (id)
CA (1) CA2233783A1 (id)
CZ (1) CZ294340B6 (id)
HU (1) HUP9800744A3 (id)
ID (1) ID20117A (id)
IL (1) IL123888A0 (id)
NO (1) NO981454L (id)
NZ (1) NZ330095A (id)
PL (1) PL325667A1 (id)
RU (1) RU2212412C2 (id)
TR (1) TR199800604A2 (id)
TW (1) TW526205B (id)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972323B1 (en) 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
ATE357459T1 (de) * 1998-01-23 2007-04-15 Hoffmann La Roche Antikörper gegen mensliches il-12
EP1087993B1 (en) 1998-06-18 2008-04-02 Imed Ab Fas peptides and antibodies for modulating apoptosis
AU757961B2 (en) * 1998-09-30 2003-03-13 Sankyo Company Limited Anti-Fas antibodies
HUP0201333A3 (en) 1999-05-24 2004-11-29 Sankyo Company Ltd Chuo Ku Medicinal compositions containing anti-fas antibody
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US20070129291A1 (en) * 2001-08-01 2007-06-07 Genset S.A. Genobix agonists and antagonists for use in the treatment of metabolic disorders
JP2005509412A (ja) 2001-08-23 2005-04-14 アールエスアール リミテッド チロトロフィン（ｔｓｈ）受容体の抗原決定領域、その使用およびその抗体
ES2357225T3 (es) 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.
HUE026132T2 (en) 2004-01-07 2016-05-30 Novartis Vaccines & Diagnostics Inc M-CSF-specific monoclonal antibody and its uses
CN102170905B (zh) * 2008-08-01 2016-08-03 阿克西斯股份有限公司 骨关节炎治疗剂及预防剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0723556A4 (en) * 1993-10-14 2003-03-19 Immunex Corp FAS ANTAGONISTS AND THEIR APPLICATIONS
DE69535719T2 (de) * 1994-01-07 2009-03-19 Mochida Pharmaceutical Co. Ltd. Fas-antigenbindender ligand
AU6091496A (en) * 1995-06-07 1996-12-30 Chiron Corporation Antibodies to fas antigen capable of inhibiting apoptosis
GB9523469D0 (en) * 1995-11-16 1996-01-17 Sandoz Ltd Organic compounds

Also Published As

Publication number Publication date
TR199800604A3 (tr) 1999-10-21
AU5970198A (en) 1998-10-08
RU2212412C2 (ru) 2003-09-20
CN1207395A (zh) 1999-02-10
HUP9800744A3 (en) 2001-04-28
CZ98598A3 (cs) 1998-10-14
CZ294340B6 (cs) 2004-12-15
PL325667A1 (en) 1998-10-12
AU734758B2 (en) 2001-06-21
EP0909816A1 (en) 1999-04-21
NO981454D0 (no) 1998-03-31
HU9800744D0 (en) 1998-05-28
CA2233783A1 (en) 1998-10-01
IL123888A0 (en) 1998-10-30
HUP9800744A2 (hu) 1999-02-01
BR9803296A (pt) 2000-01-11
NZ330095A (en) 1998-12-23
KR19980080993A (ko) 1998-11-25
TW526205B (en) 2003-04-01
AR010139A1 (es) 2000-05-17
TR199800604A2 (xx) 1999-10-21
NO981454L (no) 1998-10-02

Similar Documents

Publication Publication Date Title
ID25978A (id) Antibodi anti-fas
NO901247D0 (no) Monoklonale antistoffer som reagerer med kakektin.
DE68909441T2 (de) Modifizierte Antikörper.
NO20001104D0 (no) Humaniserte antistoff mot humant gp39, sammensetninger inneholdende slike samt terapeutiske anvendelser derav
DE60042648D1 (de) Humanisierte anti-erbb2 antikörper und behandlung mit anti-erbb2 antikörper
DE68918497D1 (de) Monoklonale Mäuseantikörper gegen HIV-IP24 und ihre Verwendung in Diagnostika.
ATE504601T1 (de) Anti-cd3-antikörper zur verwendung zur induzierung von immunsuppression
DE69319662D1 (de) Monoklonale Antikörper gegen GP130-Protein
FI963004A0 (fi) Vasta-aineen muodostumista kiihottavia monoklonaalivasta-aineita
DK0800578T3 (da) Rekombinant monoklonalt anti-idiotype antistof 3H1
DE69133179D1 (de) Katalytische antikörperkomponente
DE69128543D1 (de) Monoklonale antikörper der maus
ID20117A (id) Antibodi anti-fas
ATE71411T1 (de) Monoklonale antikoerper mit spezifitaet fuer membran-assoziierte antigene.
DK0512064T3 (da) Ekstracellulære segmenter af human IgE immuno-globulinforankringspeptider og for disse specifikke antistoffer
DE3703711A1 (de) Kreuz-schuetzende monoklonale humanantikoerper und diese enthaltende mittel
FR2631239B1 (fr) Anticorps monoclonal humain et hybridome le produisant
ES2179824T3 (es) Anticuerpos humanizados reactivos contra el antigeno gpiib/iiia.
FR2773157B1 (fr) Epitopes peptidiques reconnus par des auto-anticorps antifilaggrine presents dans le serum des patients atteints de polyarthrite rhumatoide
TR199902410A2 (xx) Anti-Fas Antikorları
IT1301815B1 (it) Anticorpi monoclonali umani contro l'antigene tumorale uk114 e cellulelinfocitarie e ibridomi per la loro produzione
TH41443A (th) แอนติบอดีที่ต้าน Fas
NO872633D0 (no) Monoklonalt antistoff mot humant plasminogen, samt fremstilling derav.
TH131300B (th) ตัวแปรอิมมูโนกลูบูลินและการใช้สิ่งนั้น
ATE99333T1 (de) Immunogen und seine verwendung zur gewinnung von antikoerpern gegen haemoglobin a1c.